perkinelmer health sciences (australia) pty ltd

RHS Limited (ASX:RHS) is at the forefront of single cell genomic analysis. Genetics is changing the world of medicine and accelerating biomedical research. The ability to cost effectively sequence the entire human genome has already led to significant medical and scientific breakthroughs. We play an important role in the critical first steps within this genetics revolution. For instruments to be able to sequence DNA, they often needs thousands, if not millions of cells worth of DNA. However, often there is very little DNA to work with. RHS with DOPlify has a core technology platform that is optimised to take DNA from a single cell and amplify it, resulting in a sample that can then be sequenced and analysed. Using DOPlify as part of the sample preparation process can lead to improved sensitivity of the sequencing and better analysis of the data. RHS has a culture of continuous innovation and invests heavily in R&D. We pride ourselves on staying up to date with innovations in genomics and continuing to push the technical boundaries of products and applications in the field. For more information about RHS and our products, services, and training please visit the website at http://www.rhsc.com.au/